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Patients with Rett syndrome (RTT) have severe mental and physical disabilities. The 
majority of RTT patients carry a heterozygous mutation in methyl-CpG binding protein 
2 (MECP2), an X-linked gene encoding an epigenetic factor crucial for normal nerve cell 
function. No curative therapy for RTT syndrome exists, and cellular mechanisms are 
incompletely understood. Here, we developed a CRISPR/Cas9-mediated system that 
targets and corrects the disease relevant regions of the MECP2 exon 4 coding sequence. 
We achieved homologous recombination (HR) efficiencies of 20% to 30% in human cell 
lines and iPSCs. Furthermore, we successfully introduced a MECP2R270X mutation into 
the MECP2 gene in human induced pluripotent stem cells (iPSCs). Consequently, using 
CRISPR/Cas9, we were able to repair such mutations with high efficiency in human 
mutant iPSCs. In summary, we provide a new strategy for MECP2 gene targeting that 
can be potentially translated into gene therapy or for iPSCs-based disease modeling of 
RTT syndrome.
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INTRODUCTION
Rett (RTT) syndrome is a genetic neurodevelopmental disorder found predominantly in female 
infants. Disease symptoms including cognitive disabilities, decreased coordination and mobility, 
repetitive movements, and slowed brain growth typically appear after 6 to 18 months of age (Hagberg 
et al., 1983; Hagberg, 1985; Trevathan and Naidu, 1988). The RTT syndrome is caused by dominant 
negative mutations in the X-linked transcription factor methyl CpG-binding protein 2 (MECP2). 
Most mutations occur within one of two functional domains of MECP2: the highly conserved methyl 
binding domain (MDB) or the transcription repressing domain (TRD) (Rasmussen et al., 1975; Amir 
et al., 1999). Gene therapy using an adeno-associated viral vector to deliver a functional sequence of 
the MECP2 gene in vivo has been intensively investigated in mouse models (Sinnett and Gray, 2017). 
However, this approach induces toxicity and side effects due to the supraphysiological expression 
of exogenous MECP2 (Sinnett and Gray, 2017). The study by Guy et al. using conditional MECP2 
alleles has shown that by restoring the physiological expression level of MECP2, the symptoms of 
RTT syndrome could be reversed in affected adult mice (Guy et al., 2007; Clarke and Abdala Sheikh, 
2018). This study suggests that CRISPR/Cas9-mediated correction of MECP2 mutant alleles is a 
potential gene therapy for RTT.
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The type II CRISPR/Cas9 system is a RNA-guided nuclease 
providing adaptive immunity in Streptococcus pyogenes. In 
mammalian cells, Cas9 nuclease can be used for editing of 
genomic sequence by the induction of targeted DNA double-
strand breaks (DSBs). The induced DSBs are mostly repaired 
by the non-homologous end-joining (NHEJ) pathway creating 
micro-deletions/or insertions (INDELs) or, to a lesser extent, 
by the homologous recombination (HR) pathway allowing 
precise genetic manipulations if a repair template is provided 
(Cong et al., 2013; Hsu et al., 2013; Mali et al., 2013; Chu et al., 
2015). Many studies have shown that CRISPR/Cas9-mediated 
mutagenesis can lead to efficient HR in human iPSCs (Byrne et 
al., 2015; Zhang et al., 2017; Li et al., 2018).
To our knowledge, there is no previous attempt to correct 
endogenous MECP2 mutant alleles in human cells using the 
CRISPR/Cas9 system. Here, we provide a system to repair the 
mutation hotspots of the MECP2 exon 4. We achieved HR 
efficiency up to 20% to 30% in human cell lines and iPSCs. To 
show a proof of principle of our system, we precisely inserted 
the MECP2R270X mutation into the MECP2 gene in wild-type 
iPSCs. Finally, using the CRISPR/Cas9 system, we subsequently 
repaired this mutation successfully in mutant iPSCs. Overall, we 
provide an efficient strategy for MECP2 correction that is crucial 
for disease modeling and can potentially be translated into gene 
therapy of the RTT syndrome.
MATERIALS AND METHODS
Cell Culture and Reagents
HEK293 cells were maintained in DMEM (Gibco) supplied 
with 10% FBS (Gibco). K562 cells were cultured in RPMI 1640 
supplied with 10% FBS and 2 mM l-glutamine (Gibco). Human 
iPSCs (BCRT cell line) were cultured in E8 flex medium (Gibco) 
according to the manufacturer’s manual. Cas9 protein was 
purchased from NEB (M0386S), synthetic sgRNA was purchased 
from Synthego, and ssODN was ordered from IDT. To generate 
RNP complex, the Cas9 protein and synthetic sgRNA were mixed 
at ratio 1:2 and incubated at 25°C for 10 min.
CRISPR/Cas9 and Donor Vectors 
Construction
sgRNAs were designed based on CrisprGold software (Chu et al., 
2016). Forward and reverse oligos were mixed and phosphorylated 
individually. Then, annealed oligo duplexes were cloned into the 
BbsI sites of the CRISPR/Cas9-T2A reporter plasmid (Addgene, 
64216). To generate the pMECP2-T2A-mCherry reporter donor 
vector, the 5′ and 3′ homology arms (HA) were amplified from 
genomic DNA using Hercules Phusion polymerase (Agilent). 
The 5′ HA fragment was cloned into XhoI/EcoRI sites of pTV-
T2A-mCherry; the 3′ HA fragment was cloned into AsiSI/KpnI 
sites of the pTV-T2A-mCherry vector. To generate the pMECP2 
donor vector, 5-kb MECP2 fragment was amplified from genomic 
DNA, and at the cleavage site, the silent mutations were added to 
generate a new PstI recognition site.
Transfection, Electroporation, and Flow 
Cytometry
Human HEK293 cells were plated into six-well plates at 1 day before 
transfection. On the day of transfection, cells were supplied with 
fresh complete medium, and the DNA was mixed with FuGENE® 
HD Reagent (Promega) in Opti-MEM (Invitrogen) according to 
the manufacturer’s introduction. After 15 min of incubation at 
RT, the mixture was dropped slowly into the well. Next day, the 
medium was exchanged. The transfected cells were analyzed in 
different time points. For flow cytometry analysis, HEK293 cells 
were trypsinized and resuspended in PBS/1% bovine serum 
albumin (BSA) fluorescence-activated cell sorting (FACS) buffer 
and analyzed with a Fortessa machine (Becton Dickinson).
For electroporation, human K562 cells were harvested and 
counted, 2 × 105 cells were resuspended with sgRNA/Cas9 RNP 
and 100 pmol ssODN in 20 µl electroporation buffer P3 (Lonza) 
and transferred to a 16-strip cuvette and electroporated using a 
4D Nucleofector X unit (Lonza). Then, cells were transferred into 
the pre-warmed complete medium.
For human BCRT-iPSCs, we used Lipofectamine® 3000 (Life 
Technologies) according to the manufacturer’s manual. Briefly, 
1 day before transfection, iPSCs were placed as small clumps 
in 500 μg/ml of vitronectin (Life Technologies) precoated plate 
filled with E8 flex completed medium supplemented with Rock 
inhibitor (10 µM) (Bio Cat). The next day, the medium was 
replaced without Rock inhibitor 6 to 8 hours before transfection. 
Diluted plasmids and lipofectamine were prepared as described 
in manual. In the case of multiple plasmids, pX330 and targeting 
vector were used for transfection; we used a 1:1 molar ratio. 
The medium was changed on the next day to stop the reaction. 
Two days post-transfection, transfected iPSCs were collected by 
incubation with Accutase (Merck) for 5 min and the cell pellet 
was then resuspended in a medium containing E8 Flex complete 
medium, Rock inhibitor (10  µM), RevitaCell Supplement (Life 
Technologies), and Gentamycin (Lonza) (FACS-PREP medium). 
GFP+ iPSCs were sorted by FACSAria (Becton Dickinson) and 
placed into a Vitronectin-precoated plate filled with FACS-PREP 
medium. The next day, the medium was replaced by E8 flex 
completed medium. Cells were maintained in culture for several 
passages before analysis.
For introducing the MECP2R270X mutation into the MECP2 
gene, wild-type iPSCs were transfected with 2 μg of the plasmid 
expressing Cas9 and sgRNA-5 and 60 pmol of ssODN-R270X 
donor using Lipofectamine® 3000 (Life Technologies). Two days 
post-transfection, 103 GFP+ iPS cells were sorted and plated on 
a Vitronectin-coated well of a six-well plate in the FACS-PREP 
medium. The medium was changed the next day. Seven days after 
sorting, iPSC clones were picked and plated on a new Vitronectin-
coated well of a six-well plate. iPSC clones were expanded for 
2 weeks. To this end, iPSC clones were harvested for analyzing 
insertion efficiency by genotyping PCR, RFLP assay, and Sanger 
sequencing. To repair the MECP2R270X mutation, homozygous 
mutant iPSC clone (clone 18) was transfected with the plasmid 
expressing Cas9 and sgRNA-3 together with the donor template 
plasmid containing silent mutations and a recognition site of PstI 
restriction enzyme as described above.
Precise CRISPR/Cas9-Mediated MECP2 ModificationsLe et al.
3 July 2019 | Volume 10 | Article 625Frontiers in Genetics | www.frontiersin.org
Genomic DNA Isolation, PCR, T7EI, 
and RFLP Assay
Reporter+ cells were cultured and harvested at different time 
points. Single-cell clones were sorted in 96-well plates. Genomic 
DNA was extracted using the QuickExtract DNA extraction kit 
(Epicentre) following the manufacturer’s instruction. For T7EI 
assay, PCR was done using Herculase II Fusion DNA Polymerase 
(Agilent Technology) with PCR gene-specific primers (Table 1) 
using the following conditions: 98°C for 3 min; 39 cycles (95°C 
for 20 s, 60°C for 20 s, 72°C for 20 s), and 72°C for 3 min. PCR 
products were run on 2% agarose gels, purified, denatured, 
annealed, and treated with T7EI (NEB). Cleaved DNA fragments 
were separated on 2% agarose gels, and the DNA concentration 
of each band was quantified using the ImageJ software. For 
genotyping RFLP assay, PCR product was purified and digested 
with a PstI restriction enzyme for 1 h. The digestion was separated 
on 2% agarose gels.
DNA sequencing PCR products were directly sequenced 
by specific primers or cloned into the pSTBlue-1 Blunt vector 
(Novagen) following the manufacturer’s protocol. Plasmid 
DNAs were isolated using the NucleoSpin Plasmid (Macherey-
Nagel). Plasmids were sequenced using T7 forward primer 
(5′-TAATACGACTCACTATAGGG-3′) by the Sanger method 
(LGCgenomics, Berlin, Germany).
qRT-PCR
Total RNA was extracted from wild-type, mutant, and repaired 
iPSC clones with RNAeasy Mini Kit (Qiagen) and was reverse-
transcribed into cDNA with a SuperScript™ III kit (Invitrogen). 
The expression of MECP2 was measured by real-time PCR 
using SYBR green PCR Master Mix (Thermo Scientific) and 
StepOnePlus™ (Applied Biosystems). The relative expression 
level of MECP2 was normalized with GAPDH housekeeping 
gene.
Statistical Analysis
Statistical tests were performed using Prism 7.0 (GraphPad) 
using a paired two-tailed Student’s t-test. ****P <0.0001.
RESULTS
CRISPR/Cas9-Mediated Reporter 
Insertion in the MECP2 Locus
Our previous study identified the mutation spectrum of the 
MECP2 gene in Vietnamese patients with RTT syndrome. 
The recurrent mutations T158M, G269fs, R270X, and R306H 
are located in the MDB and TRD domains of MECP2 protein 
encoded by exon 4 of the MECP2 gene (Figure 1A). These 
mutations are specific for the Vietnamese patients, listed in 
RettBASE (Le Thi Thanh et al., 2018). We first developed a 
system to quantitatively determine HR efficiency in the human 
MECP2 locus by inserting in-frame the coding sequence of 
cleavage peptide (T2A) and an mCherry reporter in the last 
exon of the MECP2 gene. As a result, correctly targeted cells 
will express the mCherry reporter (Figure 1B). We used the 
CRISPRGold tool (Chu et al., 2016) to design two gRNAs 
(sg1 and sg2) targeting sequences proximal to the MECP2’s 
stop codon. T7EI assay indicated that both sgRNAs efficiently 
targeted the MECP2 locus upon delivery into HEK293 cells 
along with Cas9. Sanger sequencing showed a broad range 
of INDELs at the targeted site (Figure 1C). To access HR 
efficiency, plasmids expressing sg1 and Cas9 were transfected 
into the HEK293 cells together with donor plasmid carrying 
the MECP2_T2A_mCherry repair template. Transfected 
cells were analyzed by flow cytometry at days 14 and 21 post-
transfection. We detected about 23% of mCherry+ cells in 
HEK293 cells that received sg1, Cas9, and donor template, but 
only background signals in control groups transfected with 
sgRNA/Cas9 or donor template alone (Figure 1D and  E). 
We confirmed the corrected integration of the reporter into 
the targeted MECP2 locus by using an external forward 
primer annealing to a genomic sequence outside of the 5′ 
HA and a specific T2A sequence reverse primer for PCR. The 
expected ~3.6-kb fragment was amplified only in HEK293 cells 
transfected with sg1, Cas9, and donor template (Figure 1F). 
These data indicate the correct configuration of the HR alleles 
in mcherry+ HEK293 cells. Single mCherry+ cells were sorted 
into individual wells of 96-well plates for genotyping PCR. 
We found that about 75% of these cells harbor heterozygous 
TABLE 1 | Sequences of sgRNAs, ssODNs, and primers were used in this study. 
Name Forward (5′>>3′) Reverse (5′>>3′)
sg1 CACCGAGAGTTAGCTGACTTTACA AAACTGTAAAGTCAGCTAACTCTC
sg2 CACCGTTAGCTGACTTTACACGGAG AAACCTCCGTGTAAAGTCAGCTAAC
sg3 CACCGCTTTTTGGCCTCGGCGGCAG AAACCTGCCGCCGAGGCCAAAAAGC
sg4 CACCGGGTGGCAGCCGCTGCCGCCG AAACCGGCGGCAGCGGCTGCCACCC
sg5 CACCGTCAGGCCATTCCCAAGAAAC AAACGTTTCTTGGGAATGGCCTGAC
MECP2 T7 set 1 CCAGAGGAGGCTCACTGGAGAGCGAC GCTTGTCTGGTCAGTAGTATCTGCAGC
MECP2 T7 set 2 ACCACATCCACCCAGGTCATGGTGATC TGGTGATGGTGGTGGTGCTCCTTCTTG
MECP2 HR TAGAATAGGTAGGGTGCTCTTCTCCACCGG CGGGATTCTCCTCCACGTCACCGCATGTT
MECP2 RT-PCR GGAAATCTGGCCGCTCTGCTGGGA ATTAGGGTCCAGGGATGTGTCGCCT
Gapdh RT-PCR ATGCATCCTGCACCACCAACTGCTTAG GGATGCAGGGATGATGTTCTGGGCAGC
ssODN donor CATTCCCAAGAAACGGGGCCGAAAGCCGGGGAGTGTGGTGGCAGCAGCTGCAGCAGAGGCCAAAAAGAAAGCCGTGAAGGAGTCTTC 
TATCCGATCTGTG
ssODN R270X GGTGATCAAACGCCCCGGCAGGAAGCGAAAAGCTGAGGCCGACCCTCAGGCCATTCCCAAAAAGCGCGGCTGAAATCTAGAGAGTGTG 
GTGGCAGCCGCTGCCGCCGAGGCCAAAAAGAAAGCCGTGAAGGAGTCTTCTAT
Precise CRISPR/Cas9-Mediated MECP2 ModificationsLe et al.
4 July 2019 | Volume 10 | Article 625Frontiers in Genetics | www.frontiersin.org
integrations of the T2A-mCherry sequence into MECP2, 
whereas homozygous integrations represent about 25% 
(Figure 1G). Taken together, using CRISPR/Cas9 and reporter 
systems, we achieved efficient HR in the human MECP2 locus.
CRISPR/Cas9-Mediated Precise 
Modification in MECP2 Locus
Next, we developed the CRISPR/Cas9-mediated system to correct 
the recurrent mutations in the MECP2 exon 4: G269fs, R270X, 
and R306H. We designed two sgRNAs close to these mutations 
(sg3 and sg4) and a repair template containing HAs of 2.5 kb. 
To facilitate quantification of the HR efficiency, a PstI restriction 
site was created by introducing silent mutations into the repair 
template (Figure 2A). High editing activities of sg3 and sg4 were 
validated in HEK293 cells by T7E1 assays (Figure 2B, top panel). 
Sequencing data of sg3-targeted cells showed a broad range of 
INDELs (Figure 2B, bottom panel). Next, plasmids, carrying 
Cas9/sg3 and donor template were transfected into HEK293T 
cells. Thirty days post-transfection, genomic DNA of transfected 
FIGURE 1 | CRISPR/Cas9-mediated reporter insertion in the MECP2 locus. (A) Scheme of human MECP2 isoforms (above) and MECP2 protein with hotspot 
mutations in exon 4 (below). (B) Targeting strategy to insert T2A-mCherry into the MECP2 locus. (C) T7EI assay to show the editing activity of sg1 and sg2 
(above) in the targeted MECP2 sequence. Sequencing data (below) indicates the INDEL spectrum of sg1 in the targeted MECP2 locus. (D) The percentage of 
mCherry+ cells were analyzed by flow cytometry at days 14 and 21 post-transfection. (E) The HR efficiency was summarized in the graph from three independent 
experiments, data show means ± SD (**** p<0.0001). (F) Corrected integration PCR. (G) Mono-allelic and bi-allelic knockin analysis in single mCherry+ cell clones. 
The data represent at least two independent experiments.
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cells was isolated, and the targeted region was amplified by 
PCR. PstI-mediated restriction fragment length polymorphism 
(RFLP) showed that PstI-cleaved bands were only detected in 
cells co-transfected with sg3, Cas9, and repair template. Band 
quantification showed HR efficiency of 20% to 30% in the MECP2 
locus (Figure 2C). Sequencing data of the targeted homozygous 
clone confirmed that the precise modifications were correctly 
inserted into the MECP2 gene (Figure 2D).
It is known that HR efficiency is determined by many factors. 
The type of donor template is considered as the most important 
one (Song and Stieger, 2017). Double-stranded DNA plasmid, 
PCR sequences, and ssDNA oligonucleotides (ssODN) are 
often used as a donor template for precise insertion of large 
or small sequence changes at CRISPR/Cas9-induced DSBs. 
To test whether we can also use ssODN as donor template for 
MECP2 precise modifications, we designed a 100-nucleotide 
ssODN with homology regions of 45 nucleotides each and silent 
replacements to create a PstI restriction site (Figure 2E). Next, 
we electroporated the sg3/Cas9 RNP complexes with ssODN 
into human leukemic K562 cells. Four days post-targeting, the 
targeted cells were harvested for analyzing HR efficiency. As 
shown in Figure 2E, we detected PstI-cleaved PCR products only 
in cells that received both RNP and ssODN. The HR efficiency 
ranged from 29% to 34% (Figure 2E).
FIGURE 2 | CRISPR/Cas9-mediated efficient precise modification in the MECP2 locus. (A) A strategy to knock-in silent mutations in the MECP2 exon 4. (B) T7EI 
assay showed the cutting efficiencies of two sgRNAs (above) and sequencing data (sg3) showed the INDELs of the targeted MECP2 sequence. (C) PstI-mediated 
restriction fragment length polymorphism (RFLP) assay showed the HR efficiency in HEK cells after 30 days of transfection, numbers indicate HR efficiency.  
(D) Sanger sequencing data of single-cell clone: wild-type (WT) and homozygous targeted clone (below). (E) A strategy to knock-in silent mutations in K562 cells 
using CRISPR/Cas9 RNP and ssODN as a repair template (above) and the RFLP assay to access the knock-in efficiency. Numbers in red represent for the band 
quantification-based knock-in efficiency. The data represent at least two independent experiments.
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CRISPR/Cas9-Mediated Reporter 
Insertion in Human iPSCs
Patient-derived iPSCs have been intensively studied for disease 
modeling, drug discovery, and potential somatic cell therapy. 
Thus, we next tested whether our system works efficiently in 
human iPSCs. We exploited the reporter system as described 
above to evaluate HR efficiency. The sg1/Cas9 vector and donor 
template vector were co-transfected into human iPSCs. Two 
days later, the transfected iPSCs were enriched and expanded 
(Figure  3A). The transfection efficiency in human iPSCs was 
about 25% to 28% (Figure 3B and C). Ten days after expansion, 
the percentage of mCherry+ iPSCs was analyzed by flow 
cytometry. As shown in Figure 3D and E, the percentage of 
mCherry+ iPSCs was about 20% when transfected with sg1/Cas9 
and donor template vectors, whereas there were only background 
signals in control cells transfected with only sg1/Cas9 or donor 
FIGURE 3 | CRISPR/Cas9-mediated reporter insertion in human iPSCs. (A) Experimental scheme of gene editing in human iPSCs. (B) Transfection efficiency in 
iPSCs using Lipofectamine 3000 was analyzed by FACS. (C) A bar graph indicated the transfection efficiency of human iPSCs, data show means ± SD (****p < 0.0001). 
(D) FACS analysis showed the knock-in efficiency in human iPSCs represented by the mCherry+ cells. (E) A bar graph showed knock-in efficiencies in human iPSCs, 
data show means ± SD (****p < 0.0001). (F) Corrected integration PCR and Sanger sequencing data showed the junctions of 5′ HA. The data represent at least two 
independent experiments.
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template vectors alone (Figure 3D and E). Correct integration 
PCR proved that the T2A-mCherry reporter was successfully 
inserted into the MECP2 locus in human iPSCs (Figure 3F). 
Sequencing data confirmed that the targeted MECP2 sequences 
were configured as planned (Figure 3G). Overall, we provide 
a new efficient system to precisely modify the human MECP2 
gene in human iPSCs.
CRISPR/Cas9-Based Modeling 
MECP2R270X Mutation in Human iPSCs
To precisely introduce a MECP2R270X mutation (c.808 C>T) into 
the MECP2 gene in human iPSCs, we designed a new sgRNA 
(sg5) and ssODN (ssODN-R270X) with homology regions 
of 60 nucleotides, including the C>T mutation and an XbaI 
recognition site (Figure 4A). Next, we transfected human iPSCs 
with the sg5/Cas9 vectors and ssODN-R270X donor template. 
Two days post-transfection, the transfected iPCSs were sorted 
and single cell-derived clones were expanded (Figure 4B). To 
this end, cell clones were harvested for analyzing the insertion 
efficiency of the MECP2R270X mutation. Among 22 cell clones, 
we detected two (9%) homozygous and five (23%) heterozygous 
clones (Figure 4C and 4D). Sequencing data confirmed that we 
succeeded to insert the R270X mutation into the MECP2 gene in 
human iPSCs (Figure 4E). To show a proof of principle of our 
correction system, we used the strategy depicted in Figure 2A. 
The sg3/Cas9 and donor template vectors were transfected into 
MECP2R270X/R270X iPS cells (clone 18, see Figure 4C). Two days 
later, single cell-derived clones were isolated and expanded for 
2 weeks. As shown in Figure 4F, the PstI-mediated RFLP assay 
showed that we were able to correct the MECP2R270X mutation in 
mutant iPSCs. To assess the expression of the MECP2 gene, we 
isolated mRNA from the wild-type, mutant, and repaired iPSC 
clones. Quantitative RT-PCR data showed that we enabled to 
restore the expression level of the MECP2 gene in the repaired 
iPSCs as comparable as the wild-type iPSCs (Figure 4G). 
Sequencing data of MECP2 cDNA confirmed that the mutant 
MECP2 allele was successfully repaired in the corrected iPSCs 
(Figure 4H). Thus, this system will open new avenues to iPSC-
based disease modeling and therapeutic development of RTT 
syndrome.
DISCUSSION
In this study, we developed an efficient CRISPR/Cas9-mediated 
system that precisely modifies the human MECP2 locus. 
Restoration of the physiological expression level of the MECP2 
gene is critical for the reversion of disease symptoms. Thus, the 
correction of mutations in the endogenous MECP2 gene holds 
promise for gene therapy of RTT syndrome. Using preclinical 
mouse models of RTT, many laboratories have attempted to deliver 
intact MECP2 cDNA in vivo, using the AAV vectors (Sinnett and 
Gray, 2017). Although AAV-mediated MECP2 delivery leads to 
positive effects, such as increasing survival and improving weight, 
this system still causes multiple side effects and toxicity to animals 
due to the uncontrolled expression level of the MECP2 transgene 
(Collins et al., 2004; Luikenhuis et al., 2004; Gadalla et al., 2013). 
Thus, the expression level of MECP2 is essential for restoring 
the function of defected neurons. Too much MECP2 protein is 
as harmful to neural cells as too little. It has been shown that 
patients with the MECP2 duplication syndrome have two copies 
of the MECP2 gene on their single X-chromosome leading to 
mental disability and autistic-like behavior (Moretti and Zoghbi, 
2006). Furthermore, a reduction of MECP2 protein due to 
protein instability is also related to the milder neurological and 
psychiatric symptoms, such as anxiety and depression (Ramocki 
et al., 2009; Chao and Zoghbi, 2012). CRISPR/Cas9-mediated 
mutation correction restores the endogenous expression of the 
MECP2 gene that might fully recover RTT symptoms. This system 
can be potentially applied as gene therapy for RTT patients in 
vivo. However, many challenges remain. For example, the mainly 
affected cells are neurons that are non-dividing. It is known 
that the HR pathway occurs in the S-G2 phase of the cell cycle. 
Thus, non-dividing or low proliferating cells, such as neurons, 
are not suitable for HR-mediated mutant correction. However, 
this issue can be potentially addressed by either suppressing the 
NHEJ pathway or activating HR-related factors (Chu et al., 2015; 
Charpentier et al., 2018). In addition, the safety of the system 
needs to be further investigated.
In addition, many studies have shown that MECP2 is not 
only essential for the functions of neurons but also important 
for the functions of glial subtypes in the brain as well as of 
many cell types in the immune system, including microglia 
and macrophages (Maezawa and Jin, 2010; Derecki et al., 
2012; O’Driscoll et al., 2013; Cronk et al., 2015; Jin et al., 
2015; Cronk et al., 2016). Physiological restoration of normal 
MEPC2 functions in neurons and in all immune cells should 
be considered as an optimal therapy. It is supported that 
hematopoietic stem cell transplantation (HSCT) is beneficial in 
Mecp2-deficient mice and that MeCP2 plays important roles for 
immune cells both in the brain and in the periphery (Maezawa 
and Jin, 2010; Derecki et al., 2012; O’Driscoll et al., 2013; Cronk 
et al., 2015; Jin et al., 2015). Thus, correction of the MECP2 
mutations ex vivo with the CRISPR/Cas9 system followed by 
autologous HSCT is a promising future therapeutic option for 
RTT syndrome.
Our system also works efficiently in human iPSCs opening 
great avenues for disease modeling, drug screening, and somatic 
cell therapy. The generation of RTT patient-derived iPSCs 
(RTT-hiPSCs) has been reported by many groups; however, the 
natural random X-chromosome inactivation (XCI) status of 
RTT-hiPSCs is inconsistent. XCI results in cellular mosaicism 
where some cells express wild-type MECP2 (isogenic), whereas 
other cells express mutant MECP2. Some studies showed that the 
maintenance of inactive X-chromosome of the founder cell allows 
RTT-hiPSCs to express either wild-type or mutant MECP2 allele 
(Ananiev et al., 2011; Cheung et al., 2011; Pomp et al., 2011). 
In contrast, others reported that the inactive X-chromosome 
of the founder cells is reactivated during the reprogramming 
process (Kim et al., 2009; Marchetto et  al., 2010). Importantly, 
RTT-hiPSCs could differentiate into neurons that exhibit 
disease phenotypes of RTT syndrome. Thus, these cells will be 
valuable for being rescued by CRISPR/Cas9-mediated MECP2 
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FIGURE 4 | CRISPR/Cas9-mediated insertion of the MECP2R270X mutation in human iPSCs. (A) Strategy to insert a c.808 C>T mutation into the MECP2 gene 
using CRISPR/Cas9 system. (B) Experimental scheme of the MECP2R270X mutation insertion in human iPSCs. (C) XbaI-mediated RFLP assay shows heterozygous 
and homozygous MECP2R270X mutant iPSC clones. (D) The donut chart summarizes the data shown in (C). (E) Sanger sequencing data confirms insertion of the 
MECP2R270X mutation in homozygous mutant iPSC clone. (F) PstI-mediated RFLP assay shows successful correction of the MECP2R270X mutation in the repaired 
IPSC clones. (G) qRT-PCR data shows the expression level of MECP2 in the wild-type, homozygous mutant, and CRISPR/Cas9-repaired iPSC clones. (H) Sanger 
sequencing data of MECP2 cDNA confirms the MECP2R270X correction in the repaired iPSCs. The data represent at least two independent experiments.
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correction. Using CRISPR/Cas9 technology, we have achieved 
efficient precise MECP2 modifications in human iPSCs. Overall, 
our work provides an efficient system for repairing MECP2 
mutations in RTT-hiPSCs.
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